What is a dysembryoplastic neuroepithelial tumour?
A dysembryoplastic neuroepithelial tumour, usually shortened to DNET or DNT, is a benign, very slow-growing brain tumour. It forms in the cortex, the outer grey matter of the brain, most often in the temporal lobe.
The name reflects the idea that the tumour arises from cells that developed abnormally while the brain was forming (“dysembryoplastic”), and that it contains both nerve cells and supporting glial cells (“neuroepithelial”). It belongs to the group called glioneuronal tumours.
DNET is classed as a CNS WHO grade 1 tumour, the lowest grade. It almost never turns into a cancer, and it rarely grows much over the years.
The main problem it causes is epilepsy. Most people with DNET have focal seizures that began in childhood or adolescence, and these seizures often do not respond well to anti-seizure medicines. Surgery to remove the tumour stops seizures in most people (Bonney et al., 2016).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of tumour | Benign glioneuronal tumour of the cortex |
| WHO grade | CNS WHO grade 1 |
| How common | Rare overall; one of the commonest tumours found in surgery for long-term epilepsy |
| Typical age | Seizures usually start before age 20; diagnosis often in childhood or young adulthood |
| Sex | Slightly more common in males |
| Usual site | Temporal lobe, especially its inner part; also frontal and other lobes |
| Main symptom | Focal seizures, often drug-resistant |
| Main treatment | Surgical removal (epilepsy surgery) |
| Outlook | Excellent survival; most people become seizure-free after complete removal |
2. Causes and risk factors
The cause of DNET is not fully understood. It is not caused by head injury, infection, diet or lifestyle.
Gene changes
| Gene change | Notes |
|---|---|
| FGFR1 alterations | Found in most DNETs; include duplication of part of the gene or small mutations that keep the FGFR1 growth signal switched on |
| Other MAPK pathway changes | Occasionally, such as BRAF changes; BRAF V600E is less typical than in ganglioglioma |
| Brain development | The tumour often sits in an area of abnormal cortex (cortical dysplasia) |
These changes are acquired in the tumour and are not inherited. A small number of DNET-like tumours occur in people with neurofibromatosis type 1, but this link is uncommon.
Related epilepsy-associated tumours
| Tumour | Notes |
|---|---|
| DNET | Cortical, bubbly appearance; FGFR1 changes |
| Ganglioglioma | Cyst with a nodule; often BRAF V600E |
| Angiocentric glioma | Rare; MYB changes |
| Polymorphous low-grade neuroepithelial tumour of the young (PLNTY) | Calcified; BRAF or FGFR changes |
These tumours are often grouped together as long-term epilepsy-associated tumours (LEATs).
3. How does it look
On MRI
| Feature | Description |
|---|---|
| Position | In the cortex, extending a little into the white matter beneath |
| Shape | Triangular or wedge-shaped, pointing inwards |
| Texture | Multinodular, cyst-like or “bubbly” |
| Signal | Very bright on T2-weighted images, dark on T1 |
| FLAIR | Often a bright rim around the bubbles |
| Mass effect | Little or none; nearby structures are not pushed aside |
| Contrast enhancement | Usually absent or faint |
| Skull | Overlying bone may be thinned from long-standing pressure |
During surgery
The tumour usually looks like soft, gelatinous, slightly swollen cortex. Its edges can be hard to see by eye, which is why surgeons use MRI guidance and sometimes brain recordings during the operation.
Under the microscope
| Feature | Description |
|---|---|
| Specific glioneuronal element | Columns of small oligodendrocyte-like cells arranged along nerve fibres |
| Floating neurons | Normal-looking nerve cells floating in pools of pale, mucoid fluid |
| Nodules | Glial nodules in complex forms |
| Nearby cortex | Often shows cortical dysplasia |
| Proliferation | Very low Ki-67 |
| Molecular | FGFR1 alteration; no IDH mutation or 1p/19q codeletion |
4. Symptoms
Seizures
Seizures are the main symptom and occur in almost everyone diagnosed with DNET. They are usually focal, meaning they start in one part of the brain.
| Seizure type | What it may look like |
|---|---|
| Focal aware seizure | A strange rising feeling in the stomach, déjà vu, fear, an odd smell or taste |
| Focal impaired-awareness seizure | Staring, not responding, lip-smacking, fumbling with the hands |
| Focal to bilateral tonic-clonic seizure | Spreads to a convulsion with stiffening and jerking |
| Seizures with speech problems | If the tumour is in a language area |
Other symptoms
- Memory problems, particularly with temporal lobe tumours
- Learning or behaviour difficulties in some children, often related to frequent seizures
- Tiredness after seizures or from medicines
- Low mood or anxiety, common in long-standing epilepsy
- Headache is uncommon, because the tumour rarely raises pressure in the head
What is unusual for DNET
| Symptom | Notes |
|---|---|
| Weakness of an arm or leg | Rare; may suggest another diagnosis |
| Signs of raised pressure | Such as vomiting and blurred vision; uncommon |
| Rapidly worsening symptoms | Should prompt review of the diagnosis |
When to seek medical advice
See a doctor after any first seizure, or if a child has episodes of staring, unresponsiveness or odd repetitive movements. Call emergency services if a seizure lasts more than 5 minutes, if seizures come one after another, or if the person is injured or does not recover.
5. Diagnosis
| Test | Purpose |
|---|---|
| Medical history and witness account | Describes the seizures in detail |
| EEG (brain wave recording) | Shows where seizures start |
| Video-EEG monitoring | Records seizures on video and EEG, usually before surgery |
| MRI with epilepsy protocol | Main test; shows the typical cortical, bubbly lesion |
| Neuropsychology assessment | Measures memory, language and thinking before surgery |
| Functional MRI or Wada test | Maps language and memory in some people |
| PET or SPECT scans | Help locate the seizure focus if needed |
| Pathology after surgery | Confirms the diagnosis and tests for FGFR1 changes |
Conditions that can look similar
DNET can be confused with ganglioglioma, low-grade glioma, cortical dysplasia, cysts and oligodendroglioma. In children, a DNET can also be mistaken for other low-grade tumours with similar gene changes.
The epilepsy surgery assessment step by step
| Step | What happens |
|---|---|
| 1. Referral | To a specialist epilepsy centre, ideally soon after two medicines have failed |
| 2. Video-EEG | A stay of several days while seizures are recorded |
| 3. Detailed MRI | Confirms the lesion and its relation to important brain areas |
| 4. Thinking and memory tests | Set a baseline and predict the effect of surgery |
| 5. Team meeting | Specialists agree whether surgery is likely to help |
| 6. Decision | You or your family discuss benefits and risks before choosing |
6. Treatment
Treatment is usually led by an epilepsy surgery team, including neurologists, neurosurgeons, neuropsychologists and radiologists.
Anti-seizure medicines
Medicines are the first treatment for seizures. However, many people with DNET continue to have seizures despite trying two or more medicines, which is called drug-resistant epilepsy.
Surgery
| Approach | Notes |
|---|---|
| Lesionectomy | Removes the tumour itself |
| Extended lesionectomy | Also removes nearby abnormal cortex that may generate seizures |
| Temporal lobe resection | For tumours in the inner temporal lobe, may include the hippocampus |
| Awake surgery | Used near language or movement areas |
| Intraoperative recording (ECoG) | Helps identify seizure-producing tissue |
Early surgery is increasingly recommended, because a shorter duration of epilepsy before surgery is linked with better seizure control and development. In a review of 29 studies, the median seizure-freedom rate after surgery was 86% (Bonney et al., 2016).
Other treatments
| Option | When it is used |
|---|---|
| MRI scans only | Small tumours with well-controlled seizures |
| Laser ablation (LITT) | A less invasive option in selected centres |
| Radiotherapy or chemotherapy | Almost never needed |
| Targeted drugs (FGFR inhibitors) | Experimental; considered only for rare growing tumours |
Risks and side effects of surgery
| Risk | Notes |
|---|---|
| Memory or language changes | Depends on side and site; assessed before surgery |
| Visual field loss | Possible with temporal lobe surgery |
| Bleeding or infection | Uncommon |
| Weakness | Rare; depends on location |
| Low mood | Can occur in recovery |
What treatment involves day to day
| Part of treatment | What to expect |
|---|---|
| Pre-surgical tests | Several weeks to months of assessment |
| Hospital stay | Usually 3-7 days after surgery |
| Recovery | Return to school or work often after 4-8 weeks |
| Medicines | Usually continued for at least 1-2 years after surgery, then reduced gradually if seizure-free |
DNET in children
Many people with DNET have their first seizure in childhood. Frequent seizures at a young age can interfere with learning, attention, memory and behaviour, and the side effects of several anti-seizure medicines add to the burden.
For this reason, paediatric epilepsy teams often recommend assessment for surgery soon after medicines have failed, rather than waiting for many years (Arfuso et al., 2024). After successful surgery, many children make progress at school and in their social lives, and some can stop their medicines altogether. Schools can help with individual education plans, extra time in exams and rest breaks.
7. Outlook (prognosis)
| Measure | Usual result |
|---|---|
| Survival | Excellent; DNET is very rarely life-threatening |
| Seizure freedom after complete removal | Around 8-9 in 10 people |
| Seizure freedom after partial removal | Lower; some benefit from further surgery |
| Regrowth | Uncommon after complete removal |
| Malignant change | Extremely rare and reported only in isolated cases (Matsumura et al., 2020) |
Long-term follow-up studies show that the tumour itself usually stays stable for decades, so the focus of care is the epilepsy rather than the tumour.
Children who become seizure-free often show improvements in learning, behaviour and quality of life. Some people can stop anti-seizure medicines completely after a period without seizures.
What affects the chance of becoming seizure-free?
| Factor | Effect |
|---|---|
| Complete removal of the tumour | The most important factor for a good result |
| Removal of nearby abnormal cortex | May further improve seizure control in some people |
| Shorter epilepsy duration before surgery | Linked with better outcomes |
| Clear match between MRI and EEG findings | Makes successful surgery more likely |
8. Follow-up
| Follow-up | Purpose |
|---|---|
| Clinic review with the epilepsy team | Monitor seizures and medicines |
| MRI at intervals | Confirm complete removal and detect regrowth |
| Neuropsychology review | Track memory, learning and mood |
| Medicine reduction plan | Decide when and how to stop medicines safely |
9. Living with DNET
- Keep a seizure diary to share with your team, noting the date, time, what happened and any possible triggers
- Take medicines regularly and do not stop them without advice
- Follow seizure safety advice, such as showers instead of baths and care near water or heights
- Check the driving rules that apply after seizures and after surgery
- Ask for school support for children with learning or memory difficulties
- Look after mood and sleep, as both affect seizure control; tiredness, stress and alcohol are common seizure triggers
- Seek support from epilepsy and brain tumour charities
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is DNET a cancer? | No. It is a benign, grade 1 tumour |
| Will it spread? | No; it stays where it started |
| Is it inherited? | No |
| Will surgery cure my epilepsy? | Most people become seizure-free, especially after complete removal |
| Do I need chemotherapy or radiotherapy? | Almost never |
| Can I come off my medicines? | Many people can, after a long seizure-free period and with medical advice |
11. Questions to ask your care team
- How sure are you that this is a DNET?
- Are my seizures drug-resistant, and should I be assessed for surgery?
- What are the risks to my memory, language or vision?
- How likely am I to become seizure-free?
- How long will I need anti-seizure medicines?
- What does this mean for driving, school or work?
Resources
- Arfuso, M. et al. (2024) ‘Pediatric neuroglial tumors: a review of ependymoma and dysembryoplastic neuroepithelial tumor’, Pediatric Neurology, 156, pp. 139-146.
- Bonney, P.A. et al. (2016) ‘Review of seizure outcomes after surgical resection of dysembryoplastic neuroepithelial tumors’, Journal of Neuro-Oncology, 126(1), pp. 1-10.
- Chang, E.F. et al. (2010) ‘Seizure control outcomes after resection of dysembryoplastic neuroepithelial tumor in 50 patients’, Journal of Neurosurgery: Pediatrics, 5(1), pp. 123-130.
- Matsumura, N. et al. (2020) ‘Malignant transformation of a dysembryoplastic neuroepithelial tumor verified by a shared copy number gain of the tyrosine kinase domain of FGFR1’, Brain Tumor Pathology, 37(2), pp. 69-75.
- Wang, J. et al. (2022) ‘Preoperative MRI for postoperative seizure prediction: a radiomics study of dysembryoplastic neuroepithelial tumor and a systematic review’, Neurosurgical Focus, 53(4), E7.
- National Cancer Institute (2026) Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/brain/hp/child-astrocytoma-glioma-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.